Health Care • Biotechnology: Pharmaceutical Preparations
$80.46 ▼ -0.66
(-0.81%)
MKT CAP: $8.77B • VOL: 1.59M
52W L $29 52W H $126
CORT // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $761.4M | $675.0M | $482.4M |
| YoY Revenue Growth % | +12.8% | +39.9% | — |
| Gross Profit | $748.4M | $664.2M | — |
| Gross Margin % | 98.3% | 98.4% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $44.8M | $137.0M | $107.3M |
| Operating Margin % | 5.9% | 20.3% | 22.2% |
| Net Income (GAAP) | $99.7M | $141.2M | $106.1M |
| EBITDA (Normalized) | $45.0M | $138.7M | $124.6M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $142.0M | $198.3M | $126.7M |
| Capital Expenditures (CapEx) | $211.0K | $2.2M | $21.7M |
| Free Cash Flow (FCF) | $141.8M | $196.1M | $105.0M |
| FCF Margin % | 18.6% | 29.1% | 21.8% |
| Return on Invested Capital (ROIC %) | 5.8% | 17.3% | 2.7% |
| Cash & Short-Term Equivalents | $120.5M | $127.7M | — |
| Total Debt (Short + Long Term) | $85.0M | $72.4M | $1.20B |
| Total Stockholders' Equity | $647.8M | $679.6M | $2.45B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR CORT.